Cellectar Biosciences, Inc.
CLRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001279704
No open-market purchases or sales by Cellectar Biosciences, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $9.08M in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Cellectar Biosciences, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 26
- +6 vs. Q3 2023
- Shares held
- 8.60M
- +7.15M (+490.0%) vs. Q3 2023
- Total value
- $23.9M
- +$20.0M (+519.6%) vs. Q3 2023
- New holders
- 8
- 7 more added
- Sold out
- 2
- 5 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CLRB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 29 | $9.08M |
| Q1 2026 | 19 | $812.9K |
| Q4 2025 | 20 | $1.04M |
| Q3 2025 | 21 | $1.65M |
| Q2 2025 | 19 | $734.0K |
| Q1 2025 | 32 | $1.63M |
| Q4 2024 | 30 | $1.52M |
| Q3 2024 | 35 | $30.0M |
| Q2 2024 | 37 | $28.3M |
| Q1 2024 | 45 | $36.3M |
| Q4 2023 | 26 | $23.9M |
| Q3 2023 | 20 | $3.85M |
| Q2 2023 | 21 | $3.08M |
| Q1 2023 | 21 | $2.43M |
| Q4 2022 | 26 | $3.22M |
| Q3 2022 | 22 | $2.14M |
| Q2 2022 | 33 | $3.61M |
| Q1 2022 | 32 | $4.69M |
| Q4 2021 | 42 | $4.38M |
| Q3 2021 | 40 | $6.77M |
| Q2 2021 | 46 | $14.9M |
| Q1 2021 | 45 | $24.2M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Cellectar Biosciences, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc. | 2,005,658 | $5.56M | 4.65% | +2,005,658 | New |
| AIGH Capital Management LLC | 1,915,220 | $5.31M | 2.10% | +1,237,709+182.7% | Added |
| ADAR1 Capital Management, LLC | 1,378,082 | $3.82M | 1.71% | +1,378,082 | New |
| Nantahala Capital Management, LLC | 1,350,578 | $3.74M | 0.37% | +1,350,578 | New |
| Worth Venture Partners, LLC | 693,909 | $1.92M | 1.04% | +414,786+148.6% | Added |
| Vanguard Group Inc | 482,890 | $1.34M | 0.00% | +307,006+174.6% | Added |
| Acuta Capital Partners, LLC | 477,500 | $1.32M | 0.74% | +356,200+293.7% | Added |
| Citadel Advisors LLC | 69,007 | $191.1K | 0.00% | +69,007 | New |
| Geode Capital Management, LLC | 68,870 | $190.8K | 0.00% | +6,022+9.6% | Added |
| BlackRock Inc. | 57,042 | $158.0K | 0.00% | 00.0% | Unchanged |
| GWM Advisors LLC | 21,013 | $77.5K | 0.00% | +21,013 | New |
| Coastal Bridge Advisors, LLC | 23,000 | $63.7K | 0.02% | +23,000 | New |
| State Street Corp | 15,714 | $43.5K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 15,056 | $41.7K | 0.00% | +56+0.4% | Added |
| Northern Trust Corp | 12,686 | $35.1K | 0.00% | +12,686 | New |
| Commerce Bank | 12,000 | $33.2K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 3,686 | $10.2K | 0.00% | −2,278−38.2% | Reduced |
| UBS Group AG | 1,200 | $3.32K | 0.00% | −56−4.5% | Reduced |
| Advisor Group Holdings, Inc. | 521 | $1.44K | 0.00% | −21−3.9% | Reduced |
| US Bancorp | 285 | $789 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 60 | $166 | 0.00% | −11−15.5% | Reduced |
| Harbour Investments, Inc. | 40 | $111 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 20 | $55 | 0.00% | +9+81.8% | Added |
| FMR LLC | 18 | $50 | 0.00% | −30−62.5% | Reduced |
| AllSquare Wealth Management LLC | 18 | $50 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 16 | $44 | 0.00% | +16 | New |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −21,690−100.0% | Sold out |
| Wealth Enhancement Advisory Services, LLC | 0 | $0 | 0.00% | −12,000−100.0% | Sold out |